InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics on Jul 06 2026. The amendment clarifies the sequence of closing steps, including a pre-closing name change to Mentari Therapeutics, a redomestication to Nevada before the merger filing, and any required Nasdaq reverse split before the first merger effective time. It also introduces a Company PIPE Amendment to enable potential additional pre-closing financing for Mentari and explains how such proceeds would affect the exchange ratio. The amendment confirms the combined mergers are intended to qualify as a tax-free reorganization under Section 368(a).
Agreement details:
- Agreement type: Amendment No. 1 to Agreement and Plan of Merger and Reorganization
- Counterparty: Mentari Therapeutics
- Signed / Effective: Jul 06 2026 / same
- Duration / Termination: N/A
- Reason: Clarify steps, financing flexibility and tax treatment for the merger
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.